-
Mashup Score: 1Initial Impressions and Comparison to Typical Cases - 25 day(s) ago
Dr. Bose discusses his initial impressions of the case and how it compares to typical myelofibrosis cases seen in his practice.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 27
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization To create an adaptation, translation, or derivative of the original work, for commercial e-pr ints and printed articles further permission is required. For information contact: marketing@haematologica.org
Source: haematologica.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis | Blood Cancers Today - 2 month(s) ago
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with JAKi-naïve myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT? | Blood Cancers Today - 2 month(s) ago
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT? | Blood Cancers Today - 3 month(s) ago
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3TP-3654 Monotherapy Well-tolerated in Relapsed or Refractory Myelofibrosis | Blood Cancers Today - 3 month(s) ago
Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6EBMT, ELN Working Group Publish Updated Guidelines for HSCT in Myelofibrosis | Blood Cancers Today - 3 month(s) ago
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis | Blood Cancers Today - 3 month(s) ago
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with JAKi-naïve myelofibrosis.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
Prithviraj Bose, MD, of @MDAndersonNews discusses his initial impressions of the case and how it compares to typical #myelofibrosis cases seen in his practice. https://t.co/SWowCkLXYm